B. Riley analyst Mayank Mamtani reiterates a Buy rating on Altimmune with a $20 price target following the company’s Q2 report. Altimmune provided key updates focused on its lead candidate, pemvidutide, the analyst tells investors in a research note. The firm remains a buyer of the stock “heading into a slew” of conference updates 2024. Altimmune has a Phase II metabolic dysfunction-associated steatohepatitis “best-in-industry” study execution underway with a future Phase III to benefit from fast-evolving regulatory and commercial dynamics, contends the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune reports Q2 EPS (35c), consensus (34c)
- Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
- ALT Earnings this Week: How Will it Perform?
- Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
- Altimmune announces publication of study of pemvidutide in MASLD